Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Litoxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 12/20 | 0.97 |
| ▸ | SLC6A4 known ✓ | P31645 | 12/20 | 0.97 |
| ▸ | SLC6A3 known ✓ | Q01959 | 11/20 | 0.97 |
| ▸ | HTR3A known ✓ | P46098 | 2/20 | 0.97 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.97 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.97 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.97 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.97 |
| ▸ | HTR4 known ✓ | Q13639 | 1/20 | 0.97 |
| ▸ | KCNH2 known ✓ | Q12809 | 6/20 | 0.81 |
| ▸ | REN known ✓ | P00797 | 7/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Litoxetine SCHEMBL30505553 | 0.98 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3HTR3AHTR2A | |
| Litoxetine SCHEMBL119884 | 0.98 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3HTR3AHTR2A | |
| SCHEMBL14342835 | 0.90 | SLC6A2 (1.00) | SLC6A2SLC6A4SLC6A3HTR3AHTR2A | |
| Litoxetine SCHEMBL10658612 | 0.87 | SLC6A2 (0.78) | SLC6A2SLC6A4SLC6A3HTR3AHTR2A | |
| Litoxetine SCHEMBL10658633 | 0.87 | SLC6A2 (0.78) | SLC6A2SLC6A4SLC6A3HTR3AHTR2A | |
| SCHEMBL18616440 | 0.84 | SLC6A2 (0.74) | SLC6A2SLC6A4SLC6A3HTR3AHTR2A | |
| Hydrochloric Acid SCHEMBL8493603 | 0.83 | SLC6A2 (0.82) | SLC6A2SLC6A4SLC6A3HTR3AHTR2A | |
| Hydrochloric Acid SCHEMBL8484912 | 0.82 | SLC6A2 (0.72) | SLC6A2SLC6A4SLC6A3HTR3AHTR2A | |
| SCHEMBL8489912 | 0.81 | SLC6A2 (0.84) | SLC6A2SLC6A4SLC6A3HTR3AHTR2A | |
| Hydrochloric Acid SCHEMBL1532893 | 0.80 | SLC6A2 (0.64) | SLC6A2SLC6A4SLC6A3HTR3AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205088-B1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | BURNHAM INSTITUTE FOR MEDICAL RES (US) | 2018-02-21 | — | — | EP | disclosed |
| EP-2418942-B1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | SANFORD-BURNHAM MEDICAL RES INST (US) | 2017-08-23 | — | — | EP | disclosed |
| US-9115061-B2 | Naphthalene-based inhibitors of anti-apoptotic proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2015-08-25 | — | — | US | disclosed |
| US-8937193-B2 | Apogossypolone derivatives as anticancer agents | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2015-01-20 | — | — | US | disclosed |
| US-8487131-B2 | Optically pure apogossypol derivative as pan-active inhibitor of anti-apoptotic B-cell lymphoma/leukemia-2 (BCL-2) | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2013-07-16 | — | — | US | disclosed |
| US-8436207-B2 | Naphthalene-based inhibitors of anti-apoptotic proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2013-05-07 | — | — | US | disclosed |
| EP-2485721-A2 | APOGOSSYPOLONE DERIVATIVES AS ANTICANCER AGENTS | Sanford-Burnham Medical Research Institute (US) | 2012-08-15 | — | — | EP | disclosed |
| EP-2418942-A1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | Sanford-Burnham Medical Research Institute (US) | 2012-02-22 | — | — | EP | disclosed |
| US-20120015992-A1 | Napthalene-Based Inhibitors of Anti-Apoptotic Proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120004311-A1 | OPTICALLY PURE APOGOSSYPOL DERIVATIVE AS PAN-ACTIVE INHIBITOR OF ANTI-APOPTOTIC B-CELL LYMPHOMA/LEUKEMIA-2 (BCL-2) | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2012-01-05 | — | — | US | disclosed |
| EP-2214674-A1 | INHIBITORS OF ANTI-APOPTOTIC PROTEINS | Burnham Institute for Medical Research (US) | 2010-08-11 | — | — | EP | disclosed |
| EP-2205088-A1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | Burnham Institute for Medical Research (US) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009129317-A1 | AN INHIBITOR OF ANTI-APOPTOTIC PROTEINS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-10-22 | — | — | WO | disclosed |
| US-20090258914-A1 | Inhibitor of Anti-Apoptotic Proteins | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-10-15 | — | — | US | disclosed |
| US-20090124675-A1 | INHIBITORS OF ANTI-APOPTOTIC PROTEINS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090105319-A1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-04-23 | — | — | US | disclosed |
| WO-2009052440-A1 | INHIBITORS OF ANTI-APOPTOTIC PROTEINS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009052443-A1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-04-23 | — | — | WO | disclosed |
| US-6552014-B2 | Administering selective serotonin reuptake inhibitor (SSRI), wherein the SSRI prevents the reduction of serotonin in blood of the individual, and the SSRI is selected from venlafaxine, venlafaxine metabolite, mirtazapine, buspirone | HEARTDRUG RESEARCH, L.L.C. | 2003-04-22 | — | — | US | disclosed |
| US-20020013343-A1 | Methods of inhibiting platelet activation with selective serotonin reuptake inhibitors | HEARTDRUG RESEARCH, L.L.C. | 2002-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258914-A1 | Inhibitor of Anti-Apoptotic Proteins | BCL2, BAX, API5 | SLC6A2 4707/4885SLC6A4 4706/4885SLC6A3 4752/4885 |
| US-20090105319-A1 | NAPHTHALENE-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS | HAX1, BAX, APOL1 | SLC6A2 4111/4885SLC6A4 4140/4885SLC6A3 4404/4885 |
| US-20120004311-A1 | OPTICALLY PURE APOGOSSYPOL DERIVATIVE AS PAN-ACTIVE INHIBITOR OF ANTI-APOPTOTIC B-CELL LYMPHOMA/LEUKEMIA-2 (BCL-2) | BCL3, BCL9, BCL2 | SLC6A2 4540/4885SLC6A4 4817/4885SLC6A3 4667/4885 |
| US-20120015992-A1 | Napthalene-Based Inhibitors of Anti-Apoptotic Proteins | HAX1, PRDX1, APOL1 | SLC6A2 3733/4885SLC6A4 3627/4885SLC6A3 4215/4885 |
| US-20090124675-A1 | INHIBITORS OF ANTI-APOPTOTIC PROTEINS | BAX, BCL2, BAK1 | SLC6A2 4368/4885SLC6A4 4127/4885SLC6A3 4256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.